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Abstract
Introduction:	Benign	and	precancerous	endometrial	hyperplasias	 (EH)	are	differenti‐
ated	 according	 to	 two	 alternative	 histomorphologic	 classifications:	 World	 Health	
Organization	(WHO)	or	endometrial	 intraepithelial	neoplasia	(EIN)	system.	The	2017	
European	 Society	 of	 Gynaecological	Oncology	 guidelines	 recommend	 paired	 box	 2	
protein	(PAX2)	immunohistochemistry	to	identify	precancerous	EH.	However,	methods	
for	interpreting	immunostaining	and	diagnostic	accuracy	are	not	defined,	and	the	role	
of	PAX2	in	endometrial	carcinogenesis	is	unclear.	We	aimed	to	assess:	(a)	PAX2	expres‐
sion	throughout	endometrial	carcinogenesis,	from	normal	endometrium	to	benign	EH,	
precancerous	EH,	and	endometrial	cancer	 (EC);	 (b)	 the	diagnostic	accuracy	of	PAX2	
immunohistochemistry	in	diagnosing	precancerous	EH,	defining	criteria	for	its	use.
Material and methods:	Electronic	databases	were	searched	for	from	their	 inception	to	
July	2018.	All	studies	evaluating	PAX2	immunohistochemistry	in	normal	endometrium,	
EH,	and	EC	were	included.	Univariate	comparisons	of	PAX2	expression	were	performed	
with	Fisher's	exact	test	(significant	P	<	.05).	Sensitivity,	specificity,	positive	and	negative	
likelihood	ratio,	diagnostic	odds	ratio	(DOR),	and	area	under	the	curve	on	summary	re‐
ceiver	operating	characteristic	curves	were	calculated.	Subgroup	analyses	were	based	on	
expression	thresholds	(decrease	vs.	complete	loss)	and	classifications	used	(WHO	vs.	EIN).
Results:	 Six	 studies	with	266	normal	endometrium,	586	EH,	 and	114	EC	were	 in‐
cluded.	Both	decrease	and	complete	loss	of	PAX2	expression	were	significantly	more	
common	in	EC	and	precancerous	EH	than	benign	EH.	Diagnostic	accuracy	was	mod‐
erate	for	both	PAX2	complete	loss	and	decrease	(areas	under	the	curve	0.829	and	
0.876,	respectively).	PAX2	complete	loss	with	EIN	system	showed	the	best	results	
(sensitivity	=	0.72;	specificity	=	0.95;	DOR	=	43.13).
Conclusions:	PAX2	seems	to	behave	as	a	tumor	suppressor	in	endometrial	carcino‐
genesis.	PAX2	is	an	accurate	marker	of	precancerous	EH;	complete	loss	of	PAX2	and	
EIN	classification	appear	as	the	optimal	diagnostic	criteria.
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1  | INTRODUC TION
Endometrial	hyperplasia	(EH)	is	an	irregular	proliferation	of	endome‐
trial	glands	with	an	increased	gland	to	stroma	ratio	when	compared	
with	 the	normal	endometrium	 (NE)	 in	 the	proliferative	phase.1 EH 
may	be	a	benign	process,	caused	by	an	unbalanced	action	of	estro‐
gens,	or	a	precancerous	process.2,3
These	two	conditions	are	managed	in	different	ways:	benign	EH	
with	observation	alone,	or	with	progestins	 if	symptomatic;	prema‐
lignant	EH	with	a	 total	hysterectomy,	or	a	conservative	progestin‐
based	treatment	(with	or	without	hysteroscopic	resection)	and	close	
follow	up	in	designated	cases.4‐6	Thus,	it	is	fundamental	to	differen‐
tiate	these	two	processes.
In	this	regard	two	classification	systems	have	been	proposed:	the	
World	Health	Organization	(WHO)	system	and	the	endometrial	in‐
traepithelial	neoplasia	(EIN)	system.2,3
The	WHO	system	categorizes	EH	into	“EH	without	atypia”	(be‐
nign)	and	“EH	with	atypia”	(premalignant)	based	on	the	presence	of	
cytologic	 atypia.1,2	 The	 former	WHO	 classification	 also	 classified	
EH	based	on	architectural	complexity	in	“simple	EH”	and	“complex	
EH.”2,3	WHO	classification	is	recommended	by	the	Royal	College	of	
Obstetricians	and	Gynaecologists.4
The	 EIN	 system	 categorizes	 EH	 into	 “benign	 EH”	 and	 “endo‐
metrial	 intraepithelial	neoplasia,”	based	on	a	combination	of	histo‐
morphologic	 criteria.2,3	 EIN	 classification	 is	 recommended	 by	 the	
American	College	of	Obstetricians	and	Gynecologists.5
On	 the	 other	 hand,	 the	 revised	 2014	WHO	 classification	 has	
used	 “atypical	 EH”	 and	 “endometrial	 intraepithelial	 neoplasia”	 as	
synonyms.1
Recently,	a	novel	 integration	of	both	classification	systems	has	
been	proposed	 in	order	 to	stratify	 the	risk	of	coexistent	cancer	 in	
premalignant	EH.	This	novel	classification	categorized	EH	into	three	
categories:	benign	EH,	EIN	without	cytologic	atypia	(at	 lower	risk),	
and	EIN	with	cytologic	atypia	(at	higher	risk).7
To	date,	histologic	examination	is	the	reference	standard	in	differ‐
ential	diagnosis	between	benign	and	premalignant	EH.	Nonetheless,	
this	method	is	characterized	by	poor	inter‐	and	intra‐observer	repro‐
ducibility.	Unclear	features	or	tissue	paucity—may	cause	additional	
problems	in	diagnostics.3,8
In	this	regard,	several	markers	have	been	proposed	to	increase	the	
reliability	 of	 the	 differential	 diagnosis.9	 In	 particular,	 in	 the	 2017	
European	 Society	 of	 Gynaecological	 Oncology	 (ESGO)	 guide‐
lines	 (based	on	the	2016	European	Society	for	Medical	Oncology‐
ESGO‐European	Society	 for	Radiotherapy	&	Oncology	Consensus	
Conference),	 the	 immunohistochemical	 evaluation	of	paired	box	2	
protein	(PAX2)	has	been	recommended	to	distinguish	premalignant	
EH	from	benign	mimics.10	Nevertheless,	 it	 is	not	specified	 if	PAX2	
nuclear	expression	should	be	assessed	routinely	or	in	selected	cases,	
and	in	terms	of	complete	loss	or	only	decrease	of	expression.
In	 the	 literature,	 the	 changes	 of	 PAX2	 immunohistochemical	
expression	 from	NE	 to	 simple	 and	 complex	 EH	 (with	 and	without	
atypia),	 EIN,	 and	 endometrial	 cancer	 (EC)	 are	 not	 well	 defined.	
Furthermore,	it	is	unclear	if	the	PAX2 gene acts as an oncogene or 
a	 tumor	 suppressor	 in	 endometrial	 carcinogenesis.	 No	 systematic	
review	 and/or	 meta‐analysis	 analyzed	 the	 diagnostic	 accuracy	 of	
PAX2	immunohistochemical	assessment	in	the	differential	diagnosis	
between	benign	and	premalignant	EH.
Objectives	of	our	study	were:
1.	 to	 determine	 the	 behavior	 of	 PAX2	 in	 endometrial	 carcino‐
genesis,	by	assessing	the	differences	in	PAX2	expression	among	
the above‐mentioned histologic categories;
2.	 to	 determine	 the	 diagnostic	 accuracy	 of	 PAX2	 immunohisto‐
chemistry	 in	differential	diagnosis	between	benign	and	precan‐
cerous	EH,	defining	the	optimal	criteria	for	the	interpretation	of	
PAX2	 immunostaining;	 for	 this	 purpose,	 we	 planned	 to	 assess	
how	 the	 accuracy	 changes	 according	 to	 the	 index	 test	 criteria	
(PAX2	complete	loss	or	even	only	decrease	of	expression)	and	ref‐
erence	standard	criteria	(WHO	or	EIN	system).
2  | MATERIAL AND METHODS
A	protocol	suggested	for	systematic	review	and	meta‐analysis	was	
followed	to	perform	this	study.	We	designed	a	priori	 the	protocol	
defining	methods	for	collecting,	extracting,	and	analyzing	data.	All	
steps	 were	 conducted	 independently	 by	 two	 reviewers	 (AR,	 AT).	
The	two	authors	independently	performed	electronic	search,	inclu‐
sion	criteria,	eligibility	of	 the	studies,	 risk	of	bias,	data	extraction,	
and data analysis. Disagreements were resolved by discussion with 
a	third	reviewer	(GS).
The	 study	was	 reported	 according	 to	 the	 Preferred	 Reporting	
Item	 for	 Systematic	 reviews	 and	 Meta‐Analyses	 (PRISMA)	 state‐
ment11	 and	 the	 Synthesizing	 Evidence	 from	 Diagnostic	 Accuracy	
TEsts	(SEDATE)	guideline.12
K E Y W O R D S
biomarker,	cancer	precursor,	endometrial	hyperplasia,	endometrial	intraepithelial	neoplasia,	
endometrioid	adenocarcinoma,	paired	box	2	protein
Key message
PAX2	loss	is	an	accurate	diagnostic	marker	of	endometrial	
precancer.	A	complete	loss	of	PAX2	and	the	EIN	classifica‐
tion	appear	as	the	optimal	diagnostic	criteria.
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Several	 searches	 were	 conducted	 using	 EMBASE,	 OVID,	
MEDLINE,	Scopus,	Web	of	Sciences,	Cochrane	Library,	ClinicalTrial.
gov,	 and	Google	Scholar	 as	 electronic	databases.	The	 relevant	 arti‐
cles	were	searched	from	the	inception	of	each	database	to	July	2018,	
by	using	a	combination	of	the	following	text	words	and	all	their	syn‐
onyms	found	in	the	Medical	SubHeading	(MeSH)	vocabulary:	“PAX2”;	
“PAX‐2”;	“Paired	box	gene	2”;	“marker”;	“biomarker”;	“diagnosis”;	“im‐
munohistochemical”;	 “immunohistochemistry”;	 “endometrial	 hyper‐
plasia”;	 “endometrial	 intraepithelial	 neoplasia”;	 “EIN”;	 “precancer”;	
“precancerous”;	 “premalignant”;	 “precursor.”	 Review	 of	 articles	 also	
included	the	abstracts	of	all	references	retrieved	from	the	search.
All	peer‐reviewed	prospective	or	retrospective	studies	evaluat‐
ing	immunohistochemical	nuclear	expression	of	PAX2	on	histologic	
samples	of	NE,	benign	EH	(EH	without	atypia/benign	EH),	precan‐
cerous	EH	(atypical	EH/EIN)	or	EC	were	included	in	the	systematic	
review.	 Exclusion	 criteria	 were:	 sample	 size	 <10	 cases;	 language	
other	than	English;	case	reports.
For	 the	meta‐analysis,	 only	 the	 studies	 assessing	 both	 benign	
and	precancerous	EH	were	included.	Exclusion	criteria	were:	immu‐
nohistochemical	assessment	of	PAX2	expression	as	a	mean	staining	
score;	evaluation	of	only	specific	categories	of	EH	(eg,	EH	with	squa‐
mous	morules,	EH	on	polyps);	overlapping	patient	data	with	a	study	
already included.
Following	 the	 revised	 Quality	 Assessment	 of	 Diagnostic	
Accuracy	 Studies	 (QUADAS‐2),13	 four	 domains	 regarding	 risk	 of	
bias	were	 evaluated	 in	 each	 study:	 (1)	 patient	 selection	 (ie,	 if	 the	
patients	were	 consecutive);	 (2)	 index	 test	 (ie,	 if	 the	 assessment	of	
PAX2	 expression	was	 unbiased,	 eg,	 index	 test	 blinded	with	 refer‐
ence	standard,	clearly	specified	method	to	 interpret	 immunostain‐
ing);	(3)	reference	standard	(ie,	if	the	histomorphologic	examination	
was	unbiased,	eg,	blinded	re‐evaluation	of	specimens);	(4)	flow	and	
timing	(ie,	if	all	patients	were	assessed	with	both	index	and	reference	
standard;	if	all	patients	were	assessed	with	the	same	tests,	if	the	la‐
tency	time	between	index	and	reference	standard	did	not	affect	the	
results).	Review	authors’	 judgments	were	categorized	as	“low	risk,”	
“unclear	risk,”	or	“high	risk”	of	bias.
Concerns	 about	 applicability	 were	 also	 evaluated	 for	 the	 do‐
mains	1,	2,	and	3	(ie,	if	the	criteria	used	are	correct	but	do	not	fit	the	
objective	of	our	review).
Data	from	each	eligible	study	were	extracted	without	modifica‐
tion	of	original	data.
Two‐by‐two	contingency	tables	were	elaborated	for	each	study,	
reporting	two	qualitative	variables:
1.	 PAX2	 nuclear	 expression	 (alternately	 dichotomized	 as	 “loss”	 or	
“presence”	 and	 “decrease”	 or	 “normal	 expression”);
2.	 histologic	category	(NE,	benign	EH,	precancerous	EH	and	EC).
“PAX2	decrease”	indicated	an	expression	at	least	decreased,	also	
including	a	complete	loss	of	expression.
For	 meta‐analysis	 of	 diagnostic	 accuracy,	 the	 index	 test	 was	
PAX2	nuclear	expression,	whereas	the	reference	standard	was	his‐
tologic	type	of	EH,	dichotomized	as	“benign”	or	“precancerous”.
Precancerous	 cases	 with	 PAX2	 loss	 or	 decrease	 were	 consid‐
ered	as	true	positives,	benign	cases	with	PAX2	presence	or	normal	
expression	were	considered	as	true	negatives,	precancerous	cases	
with	PAX2	presence	or	normal	expression	were	considered	as	false	
negatives,	and	benign	cases	with	PAX2	loss	or	decrease	were	con‐
sidered	as	false	positives.
Data	regarding	the	index	test	were	extracted	using	the	following	
criteria:
1.	 for	 the	 study	 assessing	 the	 rate	 of	 PAX2‐stained	 cells,	 PAX2	
loss	was	considered	as	0%	cell	staining,	whereas	PAX2	decrease	
was	 1%‐75%	 cell	 staining;
2.	 for	the	study	adopting	a	qualitative	staining	score	(normal,	com‐
plete	loss,	noticeably	decreased,	or	increased	staining	compared	
with	background	endometrium),	PAX2	“complete	loss”	was	con‐
sidered	as	 loss,	while	PAX2	“noticeably	decreased”	was	consid‐
ered as a decrease;
3.	 for	the	study	adopting	a	quantitative	staining	score	(0‐6)	composed	
by	both	intensity	and	proportional	score,	PAX2	loss	was	considered	
as	a	score	of	0/6,	whereas	PAX2	decreased	as	a	score	of	2‐3/6.
Data	regarding	the	reference	standard	were	extracted	by	using	the	
following	criteria:
F I G U R E  1  Flow	diagram	of	studies	identified	in	the	systematic	
review	(PRISMA	template	[Preferred	Reporting	Item	for	Systematic	
Reviews	and	Meta‐analyses])
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1.	 for	 the	 studies	 adopting	 the	WHO	 system,	 atypical	 EH	 (simple	
or	complex)	was	considered	as	 “precancerous,”	and	EH	without	
atypia	 (simple	 or	 complex)	 was	 considered	 as	 “benign”;
2.	 for	the	studies	using	the	EIN	system,	EIN	was	considered	as	“pre‐
cancerous,”	and	benign	EH	was	considered	as	“benign.”
We	contacted	doctor	Levent	Trabzonlu	to	obtain	additional	unpub‐
lished	data	from	his	study,14	regarding	PAX2	expression	in	benign	EH,	
as	recommended	by	the	SEDATE	guideline.12
Data	were	also	subdivided	into	four	subgroups	based	on	the	clas‐
sification	system	adopted	(WHO	or	EIN)	and	the	immunohistochem‐
ical	expression	of	PAX2	(loss	or	decrease).
Univariate	 comparisons	 of	 PAX2	 expression	 were	 performed	
with	Fisher's	exact	test	for	two‐tailed	P value with α	=	0.05	being	the	
significance	level	for	each	histologic	category.	Two	included	studies	
were	excluded	from	this	analysis,	because	one	assessed	PAX2	ex‐
pression	as	a	mean	staining	score15	and	the	other	had	overlapping	
patient	data	with	a	study	already	included.16
TA B L E  1   Immunohistochemical	assessment	of	PAX2	expression	in	the	included	studies
Study (ref)
Normal endometrium
Benign EH Precancerous EH
Endometrial cancerSimple EH (WHO) Complex EH (WHO)
Benign  
EH (EIN) Atypical EH (WHO) Premalignant EH (EIN)
n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS
Monte	
201018
191 68	
(35.6)
68	(35.6) — — — — — — — — — — — — — — — — — 52 37	
(71.2)
37	
(71.2)
— 62 48	
(77.4)
48	(77.4) —
Allison 
201219
28 0	(0) 5	(17.6) — 23 4	(17.4) 15 
(65.2)
— 84 49	(59) 76	(90.5) — — — — — 56 40	
(74.1)
52	(92.9) — ‐ — — — 15 3	(20) 14	(90.3) —
Kahraman 
201215
37 — — 80.8 ± 
18.5
— — — — 18 — — 88.6	±	
20.6
— — — — 19 — — 92.7	±	
11.6
— — — — 47 — — 99.2 ± 
1.2
Upson	
201216
— — — — — — — — 73 — 66	(90.4) — — — — — 41 — 38	(92) — — — — — — — — —
Joiner 
201417
10 4	(40) 4	(40) — 7 0	(0) 1	(14.3) — 25 13	(52) 15	(60) — 26 3	(11.5) 6	(23.1) — 25 20	(80) 22	(88) — 39 33 
(84.6)
35 
(89.7)
— — — — —
Trabzonlu 
201714
— — — — — — — — — — — — 34 0	(0) 7	(20.6) 4.32	±	
1.06
— — — — 15 6	(40) 11 
(73.3)
2.19 ± 
2.34
— — — —
Total 229	+	37 72	
(31.4)
77	
(33.6)
— 30 4	(13.3) 16	
(53.3)
109	+	91 62	
(56.9)
91 
(83.5)+66
— 60 3	(5) 13 
(21.7)
— 81	+	
60
60	
(74.1)
74	
(91.4)+38
— 106 76	
(71.7)
83 
(78.3)
— 77	+	47 51 
(66.2)
62	(80.5) —
n	=	199	+	91	−	L	=	69	(34.7)	−	D	=	120	(60.3) n	=	187	+	60	−	L	=	136	(72.7)	−	D	=	157	(84)+38
D,	PAX2	expression	at	least	decreased;	EH,	endometrial	hyperplasia;	EIN,	endometrial	intraepithelial	neoplasia;	L,	complete	loss	of	PAX2	expression;	 
MS,	PAX2	mean	score;	n,	number	of	specimens;	WHO,	World	Health	Organization.
TA B L E  2  Characteristics	of	the	included	studies
Study (ref) Country
Period of 
recruitment
Study 
design Specimen type
Patients 
selection
Patients age
Confounding 
factors evaluated
Immunohistochemistry
Method to assess PAX2 stainingNormal/benign EH
Malignant/ 
premalignant
Antibody 
manufacturer Clone Diluition Antigen retrieval
Monte	201018 USA 2006‐2008 n.r. Biopsies,	curettages Consecutive 41.8	±	6.1 50.3 ± 10.1 Clinical indication, 
sampling	device,	
age
Invitrogen Z‐RX2 1:300 Microwave	antigen	retrieval	
incubated	at	4°
At	least	one	null	gland,	proportional	
score
Allison 201219 USA 1985‐2009 Cohort n.r. Randomized <39	to	>70 <39	to	>70 Age,	BMI Zymed Z‐RX2 1:100 EDTA 15 min Semi‐quantitative	proportional	
score
Kahraman 201215 Turkey n.r. n.r. Biopsies,	curettages n.r. 58	±	9.8	AE	46.0	±	3.8	
PE	48.9	±	5.3	CH
54.7	±	9.8	CAH	 
61.9	±	11.5	EC
None LifeSpan	
BioSciences
Polyclonal	
(pSer393)
1:100 CC2 solution Mean	combined	staining	score	for	
each category
Upson	201216 USA 1995‐2005 Nested	
case 
control
n.r. Consecutive <39	to	>70 <39‐	>70 Age,	BMI Zymed Z‐RX2 1:100 EDTA	15	min	40	min	at	
room	temperature
Semi‐quantitative	proportional	
score
Joiner	201417 USA 2005‐2013 n.r. Biopsies,	curettages Consecutive n.r. n.r. None Cell	Marque n.r. 7	mL	pre‐diluited EDTA	Incubated	16‐32	min	
at	37°
Comparison	with	adjacent	
endometrium
Trabzonlu	201714 Turkey 2006‐2011 n.r. n.r. Randomized 22‐72	(45.4) 36‐57	(47.6) None Zeta EP235 1/20 EDTA Intensity	score,	proportional	score,	
combined score
AE,	atrophic	endometrium;	CAH,	complex	atypical	hyperplasia;	CH,	complex	hyperplasia;	EC,	endometrial	cancer;	EH,	endometrial	hyperplasia;	 
n.r.,	not	reported;	PE,	proliferative	endometrium.
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Sensitivity,	specificity,	positive	and	negative	likelihood	ratio	(LR+	
and	LR−),	and	diagnostic	odds	ratio	(DOR)	of	both	loss	and	decrease	
of	PAX2	expression	were	calculated	for	each	study	and	as	a	pooled	
estimate	 adopting	 the	 random	 effect	 model	 of	 DerSimonian	 and	
Laird	and	reported	graphically	on	forest	plots,	with	95%	CI.
Statistical	 heterogeneity	 among	 the	 included	 studies	 was	
evaluated using the Higgins I2 statistic; heterogeneity was cate‐
gorized	 as	 null	 for	 I2	=	0%,	 insignificant	 for	 0%	< I2	≤	25%,	 low	 for	
25% < I2	≤	50%,	moderate	for	50%	<	I2	≤	75%	and	high	for	I2	>	75%.
Area	under	 the	curve	 (AUC)	was	calculated	on	summary	receiver	
operating	characteristic	(SROC)	curves.	The	diagnostic	usefulness	was	
categorized	 as	 absent	 for	AUC	≤	0.5,	 low	 for	 0.5	<	AUC	≤	0.75,	mod‐
erate	 for	 0.75	<	AUC	≤	0.9,	 high	 for	 0.9	<	AUC	<	0.97,	 very	 high	 for	
AUC	≥	0.97.
We	performed	additional	analysis	as	a	subgroups	analysis,	calcu‐
lating	sensitivity,	specificity,	LR+,	LR−,	and	DOR	separately	 for	 the	
four	subgroups.	Given	that	only	two	studies	were	suitable	for	inclu‐
sion	in	each	subgroup,	AUC	was	not	calculated.
TA B L E  1   Immunohistochemical	assessment	of	PAX2	expression	in	the	included	studies
Study (ref)
Normal endometrium
Benign EH Precancerous EH
Endometrial cancerSimple EH (WHO) Complex EH (WHO)
Benign  
EH (EIN) Atypical EH (WHO) Premalignant EH (EIN)
n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS n L (%) D (%) MS
Monte	
201018
191 68	
(35.6)
68	(35.6) — — — — — — — — — — — — — — — — — 52 37	
(71.2)
37	
(71.2)
— 62 48	
(77.4)
48	(77.4) —
Allison 
201219
28 0	(0) 5	(17.6) — 23 4	(17.4) 15 
(65.2)
— 84 49	(59) 76	(90.5) — — — — — 56 40	
(74.1)
52	(92.9) — ‐ — — — 15 3	(20) 14	(90.3) —
Kahraman 
201215
37 — — 80.8 ± 
18.5
— — — — 18 — — 88.6	±	
20.6
— — — — 19 — — 92.7	±	
11.6
— — — — 47 — — 99.2 ± 
1.2
Upson	
201216
— — — — — — — — 73 — 66	(90.4) — — — — — 41 — 38	(92) — — — — — — — — —
Joiner 
201417
10 4	(40) 4	(40) — 7 0	(0) 1	(14.3) — 25 13	(52) 15	(60) — 26 3	(11.5) 6	(23.1) — 25 20	(80) 22	(88) — 39 33 
(84.6)
35 
(89.7)
— — — — —
Trabzonlu 
201714
— — — — — — — — — — — — 34 0	(0) 7	(20.6) 4.32	±	
1.06
— — — — 15 6	(40) 11 
(73.3)
2.19 ± 
2.34
— — — —
Total 229	+	37 72	
(31.4)
77	
(33.6)
— 30 4	(13.3) 16	
(53.3)
109	+	91 62	
(56.9)
91 
(83.5)+66
— 60 3	(5) 13 
(21.7)
— 81	+	
60
60	
(74.1)
74	
(91.4)+38
— 106 76	
(71.7)
83 
(78.3)
— 77	+	47 51 
(66.2)
62	(80.5) —
n	=	199	+	91	−	L	=	69	(34.7)	−	D	=	120	(60.3) n	=	187	+	60	−	L	=	136	(72.7)	−	D	=	157	(84)+38
D,	PAX2	expression	at	least	decreased;	EH,	endometrial	hyperplasia;	EIN,	endometrial	intraepithelial	neoplasia;	L,	complete	loss	of	PAX2	expression;	 
MS,	PAX2	mean	score;	n,	number	of	specimens;	WHO,	World	Health	Organization.
TA B L E  2  Characteristics	of	the	included	studies
Study (ref) Country
Period of 
recruitment
Study 
design Specimen type
Patients 
selection
Patients age
Confounding 
factors evaluated
Immunohistochemistry
Method to assess PAX2 stainingNormal/benign EH
Malignant/ 
premalignant
Antibody 
manufacturer Clone Diluition Antigen retrieval
Monte	201018 USA 2006‐2008 n.r. Biopsies,	curettages Consecutive 41.8	±	6.1 50.3 ± 10.1 Clinical indication, 
sampling	device,	
age
Invitrogen Z‐RX2 1:300 Microwave	antigen	retrieval	
incubated	at	4°
At	least	one	null	gland,	proportional	
score
Allison 201219 USA 1985‐2009 Cohort n.r. Randomized <39	to	>70 <39	to	>70 Age,	BMI Zymed Z‐RX2 1:100 EDTA 15 min Semi‐quantitative	proportional	
score
Kahraman 201215 Turkey n.r. n.r. Biopsies,	curettages n.r. 58	±	9.8	AE	46.0	±	3.8	
PE	48.9	±	5.3	CH
54.7	±	9.8	CAH	 
61.9	±	11.5	EC
None LifeSpan	
BioSciences
Polyclonal	
(pSer393)
1:100 CC2 solution Mean	combined	staining	score	for	
each category
Upson	201216 USA 1995‐2005 Nested	
case 
control
n.r. Consecutive <39	to	>70 <39‐	>70 Age,	BMI Zymed Z‐RX2 1:100 EDTA	15	min	40	min	at	
room	temperature
Semi‐quantitative	proportional	
score
Joiner	201417 USA 2005‐2013 n.r. Biopsies,	curettages Consecutive n.r. n.r. None Cell	Marque n.r. 7	mL	pre‐diluited EDTA	Incubated	16‐32	min	
at	37°
Comparison	with	adjacent	
endometrium
Trabzonlu	201714 Turkey 2006‐2011 n.r. n.r. Randomized 22‐72	(45.4) 36‐57	(47.6) None Zeta EP235 1/20 EDTA Intensity	score,	proportional	score,	
combined score
AE,	atrophic	endometrium;	CAH,	complex	atypical	hyperplasia;	CH,	complex	hyperplasia;	EC,	endometrial	cancer;	EH,	endometrial	hyperplasia;	 
n.r.,	not	reported;	PE,	proliferative	endometrium.
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One	 study	 assessed	 EH	 according	 to	 both	 classification	 sys‐
tems.17	 Hence,	 it	 was	 included	 in	 both	 subgroups,	 whereas	 data	
according	 to	 only	 the	 EIN	 system	were	 used	 for	 total	 diagnostic	
accuracy.
The	 data	 analysis	 was	 performed	 using	Meta‐DiSc	 version	 1.4	
(Clinical	Biostatistics	Unit,	Ramon	y	Cajal	Hospital,	Madrid,	 Spain)	
and Review ManageR	5.3	(Copenhagen:	The	Nordic	Cochrane	Centre,	
Cochrane	Collaboration,	2014).
3  | RESULTS
A	total	of	207	articles	were	identified	through	database	searching.	
Forty‐nine	 articles	 remained	 after	 duplicate	 removal.	 Thirty‐three	
articles	 remained	after	 title	screening.	Fifteen	articles	were	evalu‐
ated	for	eligibility	after	abstract	screening.	Lastly,	six	studies	were	
included	in	the	systematic	review,	three	of	which	were	appropriate	
for	the	meta‐analysis.	Details	about	the	whole	process	of	study	se‐
lection	are	shown	in	Figure	1.
Among	the	six	observational	studies	included	in	the	systematic	
review,14‐19	three	were	classified	EH	according	to	the	WHO	system,	
three	according	to	the	EIN	system,	and	one	according	to	both	sys‐
tems.	A	total	of	266	NE,	587	EH,	and	114	EC	were	included.	Of	537	
EH,	247	(46%)	were	categorized	as	“precancerous”	(141	atypical	EH	
and	106	EIN)	and	290	(54%)	as	“benign”	(30	simple	EH,	200	complex	
EH	and	60	benign	EH	according	to	the	EIN	system).
Details	 about	 PAX2	 immunohistochemical	 assessment	 are	
shown in Table 1.
Characteristics	of	the	included	studies	are	summarized	in	Table	2.
Regarding	the	assessment	of	risk	of	bias	among	the	studies,	for	the	
“patient	selection”	domain,	four	studies	were	categorized	as	being	at	
low	risk	of	bias,	because	they	included	consecutive	patients,	whereas	
one	was	classified	at	unclear	 risk	because	 it	did	not	 report	 this	 in‐
formation,15	 and	 one	was	 high	 risk	 because	 it	 only	 selected	 cases	
previously	diagnosed	as	non‐atypical	hyperplasia.14 Concerns about 
the	applicability	of	this	domain	were	considered	high	for	one	study,	
because	it	assessed	only	EH	of	women	treated	with	progestin.16
For	 the	 “index	 test”	domain,	 three	studies	were	categorized	at	
low	risk	of	bias,	because	they	clearly	specified	criteria	to	define	loss	
or	decrease	of	PAX2	expression,	whereas	three	studies	were	clas‐
sified	at	unclear	 risk,	because	only	one	used	a	qualitative	 staining	
score	 to	 assess	 PAX2	 expression,17	 and	 two	 did	 not	 report	 if	 the	
index	test	was	blinded	with	reference	standard.15,19
For	the	“reference	standard”	domain,	five	studies	were	catego‐
rized	at	low	risk	of	bias	since	they	reported	a	blinded	re‐evaluation	
of	specimens,	whereas	one	was	classified	at	unclear	risk	because	this	
information	was	not	clearly	reported.15
For	the	“flow	and	timing”	domain,	all	the	included	studies	were	
categorized	 at	 low	 risk	 of	 bias,	 given	 that	 both	 the	 index	 and	 the	
reference	standard	were	performed	on	the	same	sample	and	for	all	
patients;	moreover,	 the	 latency	time	between	 index	and	reference	
standard	did	not	affect	the	results.
F I G U R E  2  A,	Assessment	of	risk	of	bias.	Summary	of	risk	of	bias	for	each	study.	Plus	sign:	low	risk	of	bias;	minus	sign:	high	risk	of	bias;	
question	mark:	unclear	risk	of	bias.	B,	Risk	of	bias	graph	about	each	risk	of	bias	item	presented	as	percentages	across	all	included	studies	
[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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No	further	applicability	concerns	were	found.
Results	of	risk	of	bias	assessment	are	shown	in	Figure	2.
Analyzing	PAX2	expression	changes	among	histologic	categories	
according	 to	 the	WHO	 system,	 PAX2	 loss	was	 significantly	more	
common	 in	 complex	 EH	 than	 simple	 EH	 and	NE	 (P < 0.0001),	 and	
in	 atypical	EH	 than	complex	EH	 (P = 0.0152).	A	decrease	of	PAX2	
expression	was	 significantly	more	 common	 in	 simple	 EH	 than	NE	
(P = 0.0429),	 in	complex	EH	than	simple	EH	(P = 0.0011),	and	in	EC	
than	simple	EH	(P = 0.0073).
Adopting	EIN	criteria,	PAX2	loss	was	significantly	more	common	
in	NE	than	benign	EH	 (P < 0.0001),	 in	EIN	than	benign	EH	and	NE	
(P < 0.0001),	 and	 in	 EC	 than	NE	 (P < 0.0001).	 PAX2	 decrease	was	
significantly	more	common	in	EIN	than	benign	EH	(P < 0.0001)	and	
NE	(P = 0.0011).
Considering	 both	 WHO	 and	 EIN	 system,	 PAX2	 loss	 was	 sig‐
nificantly	 more	 common	 in	 precancerous	 EH	 than	 benign	 EH	
(P < 0.0001),	and	in	EC	than	benign	EH	(P < 0.0001).	PAX2	decrease	
was	significantly	more	common	in	benign	EH	than	NE	(P < 0.0001),	
in	 precancerous	 EH	 than	 benign	 EH,	 and	 in	 EC	 than	 benign	 EH	
(P = 0.0017).
Details	about	PAX2	immunohistochemical	expression	are	shown	
for	each	included	study	in	Table	1.	Univariate	comparisons	of	PAX2	
F I G U R E  3  Forest	plots	of	individual	studies	and	pooled	sensitivity,	specificity,	positive	likelihood	ratio	(LR+),	negative	likelihood	ratio	
(LR−),	diagnostic	odds	ratio	of	immunohistochemistry	for	loss	(A)	and	decrease	(B)	of	paired	box	2	protein	expression	in	differential	diagnosis	
between	benign	and	premalignant	endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves	[Colour	figure	can	be	
viewed	at	wileyonlinelibrary.com]
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expression	 in	 each	 histologic	 category	with	 related	P values were 
reported	in	detail	for	WHO,	EIN,	and	both	systems	together	in	the	
Supplementary	material	(Tables	S1‐S3,	respectively).
Regarding diagnostic accuracy assessment, three studies eval‐
uating	274	EH	were	included	in	the	meta‐analysis.14,17,19	In	all,	166	
(60.6%)	of	the	total	EH	were	benign	and	108	(39.4%)	were	precan‐
cerous.	Of	 the	 total,	 160	EH	were	 categorized	 according	 to	 the	
WHO	system	and	49	according	to	the	EIN	system;	moreover,	the	
study	adopting	both	classification	systems17	assessed	65	EH	ac‐
cording	to	the	EIN	system	and	57	according	to	the	WHO	system.
Pooled	sensitivity	and	specificity	of	PAX2	loss	in	diagnosing	en‐
dometrial	precancer	with	both	WHO	and	EIN	systems	were	73%	(95%	
CI	64%‐81%)	and	66%	(95%	CI	59%‐73%),	respectively,	with	pooled	
LR+	and	LR−	of	5.08	(95%	CI	0.76‐33.85)	and	0.41	(95%	CI	0.21‐0.77),	
respectively.	Pooled	DOR	was	14.55	 (95%	CI	1.61‐131.74).	Among	
the included studies, the heterogeneity was high with I2	=	80%	for	
sensitivity, I2	=	95.7%	 for	 specificity,	 I2	=	89.1%	 for	 LR+,	 I2	=	77.4%	
for	LR−,	and	 I2	=	84%	for	DOR.	The	SROC	curves	analysis	showed	
moderate	overall	accuracy	with	an	AUC	of	0.8289.
Pooled	sensitivity	and	specificity	of	PAX2	decreases	in	diagnos‐
ing	 endometrial	 precancer	 with	 both	 classification	 systems	 were	
91%	 (95%	CI	84%‐95%)	and	37%	 (95%	CI	30%‐45%),	 respectively,	
with	 pooled	 LR+	 and	 LR−	 of	 2.45	 (95%	 CI	 0.51‐11.83)	 and	 0.23	
(95%	 CI	 0.13‐0.41),	 respectively.	 Pooled	 DOR	was	 11.37	 (95%	 CI	
3.82‐33.79).	 Among	 the	 included	 studies,	 the	 heterogeneity	 was	
moderate	 in	 sensitivity	 (I2	=	68.4%),	 high	 in	 specificity	 (I2	=	97.2%)	
and	LR+	(I2	=	96.4%),	insignificant	in	LR−	(I2	=	2.1%)	and	low	in	DOR	
(I2	=	42.2%).	The	SROC	curves	analysis	showed	moderate	overall	ac‐
curacy	with	an	AUC	of	0.8764.
Results	are	reported	graphically	on	forest	plots	in	Figure	3	and	
on	SROC	curves	in	Figure	4.
With	respect	to	subgroup	analysis,	two	studies	evaluating	both	
loss	and	decrease	of	PAX2	expression	 in	217	EH	according	 to	 the	
WHO	 system	were	 included,	 respectively	 in	 the	 first	 and	 second	
subgroups.17,19	One	hundred	and	thirty‐eight	(63.6%)	of	the	total	EH	
were	benign	and	79	(36.4%)	were	premalignant.
On the other hand, two studies evaluating both loss and de‐
crease	of	PAX2	expression	in	114	EH	according	to	the	EIN	system	
were	 included,	 respectively	 in	 the	 third	and	 fourth	 subgroups.14,17 
Sixty	 (52.6%)	 of	 the	 total	 EH	 were	 benign	 and	 54	 (47.4%)	 were	
premalignant.
In	subgroup	1	(PAX2	loss	and	WHO	system),	pooled	sensitivity	
and	specificity	of	PAX2	loss	in	diagnosing	atypical	hyperplasia	were	
76%	 (95%	CI	 65%‐85%)	 and	52%	 (95%	CI	 44%‐61%),	 respectively,	
with	pooled	LR+	and	LR−	of	1.59	(95%	CI	1.25‐2.04)	and	0.46	(95%	
CI	0.3‐0.71),	respectively.	Pooled	DOR	was	3.44	(95%	CI	1.86‐6.38).	
The	 heterogeneity	 was	 null	 in	 sensitivity	 (I2	=	0%),	 specificity	
(I2	=	0%),	and	LR−	(I2	=	0%),	insignificant	in	LR+	(I2	=	12.7%),	and	low	
in	DOR	(I2	=	30.1%).
In	subgroup	2	 (PAX2	decrease	and	WHO	system),	pooled	sen‐
sitivity	and	specificity	of	PAX2	decrease	in	diagnosing	atypical	hy‐
perplasia	were	94%	(95%	CI	86%‐98%)	and	22%	(95%	CI	16%‐30%),	
respectively,	with	pooled	LR+	and	LR−	of	0.25	(95%	CI	0.1‐0.6)	and	
0.67	 (95%	CI	0.52‐0.85),	 respectively.	Pooled	DOR	was	5.73	 (95%	
CI	2.06‐15.9).	The	heterogeneity	was	low	in	sensitivity	(I2	=	45.1%),	
high	in	specificity	(I2	=	93.8%),	and	LR+	(I2	=	87.2%),	and	null	in	LR−	
(I2	=	0%)	and	DOR	(I2	=	0%).
In	 subgroup	 3	 (PAX2	 loss	 and	 EIN	 system),	 pooled	 sensitivity	
and	 specificity	 of	PAX2	 loss	 in	 diagnosing	EIN	were	72%	 (95%	CI	
58%‐84%)	 and	 95%	 (95%	 CI	 56%‐99%),	 respectively,	 with	 pooled	
LR+	and	LR−	of	8.71	(95%	CI	3.2‐23.73)	and	0.34	(95%	CI	0.0.9‐1.26),	
respectively.	Pooled	DOR	was	43.13	(95%	CI	11.44‐162.6).	The	het‐
erogeneity	was	high	in	sensitivity	(I2	=	90.1%),	specificity	(I2	=	80.9%),	
and	LR−	(I2	=	89.6%),	and	null	in	LR+	(I2	=	0%)	and	DOR	(I2	=	0%).
In	subgroup	4	(PAX2	decrease	and	EIN	system),	pooled	sensitiv‐
ity	and	specificity	of	PAX2	decreases	 in	diagnosing	EIN	were	85%	
F I G U R E  4  Summary	receiver	operating	characteristic	curves	related	to	loss	(A)	and	decrease	(B)	of	paired	box	2	protein	expression	in	
differential	diagnosis	between	benign	and	premalignant	endometrial	hyperplasia	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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(95%	CI	73%‐93%)	and	78%	 (95%	CI	66%‐88%),	 respectively,	with	
pooled	 LR+	 and	 LR−	of	3.73	 (95%	CI	2.24‐6.19)	 and	0.22	 (95%	CI	
0.09‐0.54),	respectively.	Pooled	DOR	was	17.81	(95%	CI	6.61‐47.9).	
The	heterogeneity	was	moderate	in	sensitivity	(I2	=	52.7%)	and	LR−	
(I2	=	50.2%),	null	in	specificity	(I2	=	0%)	and	LR+	(I2	=	0%),	and	insig‐
nificant	in	DOR	(I2	=	0.7%).
Results	are	reported	graphically	in	forest	plots	for	subgroups	1	
and	2	in	Figure	5	and	for	subgroups	3	and	4	in	Figure	6.
4  | DISCUSSION
Both	complete	loss	and	decrease	of	PAX2	expression	were	signifi‐
cantly	 more	 common	 in	 EC	 and	 precancerous	 EH	 than	 in	 benign	
EH,	demonstrating	that	PAX2	expression	decreases	in	endometrial	
carcinogenesis.
In	 the	overall	 analysis,	 both	PAX2	complete	 loss	 and	decrease	
showed	moderate	diagnostic	accuracy	 in	 identifying	precancerous	
EH.	Excellent	accuracy	was	achieved	by	combining	PAX2	complete	
loss	(as	index	test)	with	EIN	classification	(as	reference	standard).
The PAX2	gene	is	a	member	of	a	paired	box	gene	family	consisting	
of	nine	components	(PAX1 to PAX9),	especially	expressed	during	the	
embryonic	development	 and	organogenesis.20	However,	PAX	pro‐
teins	are	also	involved	in	several	malignancies,	acting	as	proto‐onco‐
genes	by	transactivating	promoters	of	target	genes	that	regulate	cell	
growth,	self‐sufficiency,	apoptosis,	and	cellular	transformation.21‐23 
In	particular,	PAX2	protein	has	anti‐apoptotic	effects	binding	to	the	
regulatory	region	at	the	5′	end	of	P53	gene	and	inhibiting	its	protein	
F I G U R E  5  Forest	plots	of	individual	studies	and	pooled	sensitivity,	specificity,	positive	likelihood	ratio	(LR+),	negative	likelihood	ratio	
(LR−),	diagnostic	odds	ratio	of	immunohistochemistry	for	loss	(A)	and	decrease	(B)	of	paired	box	2	protein	expression	in	differential	diagnosis	
between	benign	and	premalignant	endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves,	for	World	Health	
Organization	subgroup	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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production	at	the	transcriptional	level.24,25	The	expression	of	PAX2	
is	 upregulated	 indirectly	 by	 the	 estrogen	 receptor	 α	 pathway.26 
Nevertheless,	to	date,	the	role	of	PAX2	and	its	changes	of	expres‐
sion in endometrial carcinogenesis are still unclear, with the common 
suggestion	that	PAX2	expression	decreases	in	EC	and	precancer	and	
a	few	studies	advocating	an	opposing	viewpoint.15,26‐28
Although	one	study	among	 those	 included	 reported	 that	PAX2	
expression	 increases	 as	 endometrial	 carcinogenesis	 progresses,15 
we	found	that	both	complete	loss	and	decrease	of	PAX2	expression	
were	significantly	more	common	in	EC	and	precancerous	EH	than	in	
benign	EH.	This	behavior	seems	to	 indicate	a	tumor	suppressor	ac‐
tion	of	the	PAX2	gene	in	endometrial	carcinogenesis.	Similar	results	
were	reported	 in	studies	assessing	PAX2	by	techniques	other	 than	
immunohistochemistry.29,30 To date, data regarding the molecular 
mechanisms	 of	 PAX2	 loss	with	 specific	 regard	 to	 endometrial	 car‐
cinogenesis	are	 lacking.	However,	pathway	models	 for	 the	possible	
tumor	 suppressor	 activity	 of	 PAX2	 in	 endometrial	 carcinogenesis	
might be suggested by studies about carcinogenesis in other tissues. 
In	 particular,	 several	 mechanisms	 have	 been	 proposed	 for	 tumor	
suppressor	activity	of	PAX2	in	ovarian	carcinogenesis.	PAX2	knock‐
down	 in	 fallopian	 tube	 epithelial	 cell	 lines	 increased	 expression	 of	
the	 stem	 cell	markers	CD44	and	SCA1	and	 reduced	 the	 capability	
of	 these	 cells	 to	 form	differentiated	epithelial	 luminal	 structures.31 
It	has	been	shown	in	murine	oviductal	epithelial	cells	that	wild‐type	
F I G U R E  6  Forest	plots	of	individual	studies	and	pooled	sensitivity,	specificity,	positive	likelihood	ratio	(LR+),	negative	likelihood	ratio	
(LR−),	diagnostic	odds	ratio	of	immunohistochemistry	for	loss	(A)	and	decrease	(B)	of	paired	box	2	protein	expression	in	differential	diagnosis	
between	benign	and	premalignant	endometrial	hyperplasia	for	endometrial	intraepithelial	neoplasia	subgroup	[Colour	figure	can	be	viewed	
at	wileyonlinelibrary.com]
     |  11RAFFONE Et Al.
p53	improves	PAX2	transcription,	while	mutant	p53	decreases.32 In 
a	fallopian	tube	model	of	ovarian	cancer	with	PAX2	and	PTEN	(phos‐
phatase	and	tensin	homolog)	loss,	re‐expression	of	PAX2	repressed	
the	oncogenic	properties	of	these	cells	and	extended	survival.32 On 
the	other	hand,	PAX2	expression	 in	a	spontaneous	ovarian	surface	
epithelium	 derived	 model	 of	 high‐grade	 serous	 ovarian	 carcinoma	
reduced	proliferation	and	metastasis	by	increasing	cyclo‐oxygenase	
subunit	 2	 and	 reducing	HTRA1	 (HtrA	 serine	 peptidase	 1)	 expres‐
sion.33	Altogether,	 these	 results	 suggest	 that	PAX2	 loss	may	be	an	
early	molecular	event	in	ovarian	cancer	progression	that	predisposes	
cells	 to	 further	mutations	 that	 can	 drive	 tumorigenesis,	 regardless	
of	the	cell	of	origin.34	Such	mechanisms	might	underlie	endometrial	
carcinogenesis.
However, a PAX2	 oncogenic	 action	 cannot	 be	 excluded	 in	 en‐
dometrial carcinogenesis, as suggested by Kahraman et al15 and 
other EC cell‐culture studies.26,27	 These	 findings	might	 indicate	 a	
PAX2	 gene	double	action	 (tumor	suppressor	and	oncogene)	 in	en‐
dometrial carcinogenesis, as well as in ovarian carcinogenesis, as 
suggested.33,34	Regarding	the	increase	of	PAX2	expression,	further	
studies	are	needed	to	define	its	significance	and	its	possible	useful‐
ness	in	differential	diagnosis	between	benign	and	precancerous	EH.
It	 is	 interesting	 to	note	 that	when	adopting	 the	WHO	system,	
both	complete	 loss	and	decrease	of	PAX2	expression	were	signifi‐
cantly	more	common	in	complex	EH	without	atypia	than	in	NE	and	
simple	EH	without	atypia.	This	finding	supports	that	the	WHO	cat‐
egory	 of	 complex	 EH	without	 atypia	might	 also	 include	 premalig‐
nant	 lesions,	 as	 suggested	by	 comparison	with	EIN	 classification.3 
Therefore,	 immunohistochemical	assessment	of	PAX2	might	assist	
histomorphologic	 examination	 to	 diagnose	 precancerous	 EH	 even	
before	the	appearance	of	overt	cytologic	atypia,	as	discussed	below.
According	 to	 our	 results,	 immunohistochemical	 evaluation	 of	
both	complete	 loss	and	decrease	of	PAX2	expression	have	a	mod‐
erate	diagnostic	accuracy	 in	differential	diagnosis	between	benign	
and	precancerous	EH,	with	AUC,	respectively,	of	0.829	and	0.876.
In	the	face	of	a	similar	diagnostic	accuracy,	PAX2	complete	loss	
showed	higher	specificity	and	DOR,	but	lower	sensitivity	than	PAX2	
decrease.	This	finding	suggests	that	a	decrease	of	PAX2	may	occur	
in	an	early	stage	in	endometrial	carcinogenesis,	but	also	exists	in	a	
major	percentage	of	benign	EH	without	malignant	potential.	Instead,	
a	complete	loss	of	PAX2	may	be	a	later	and	more	specific	event	of	
precancerous	EH,	with	a	major	diagnostic	value	 in	 the	challenging	
cases	on	histologic	examination.	On	the	other	hand,	PAX2	normal	
expression	may	be	strongly	indicative	of	benign	EH.
Through	subgroup	analysis,	we	found	that	the	diagnostic	accu‐
racy	of	both	PAX2	complete	 loss	and	decrease	was	higher	when	
the	EIN	system	was	used	as	reference	standard.	In	fact,	using	EIN	
criteria,	 sensitivity,	 specificity,	 and	 DOR	 greatly	 increased.	 The	
highest	 diagnostic	 accuracy	 was	 found	 for	 the	 combination	 of	
PAX2	complete	 loss	 (as	 index	 test)	 and	EIN	system	 (as	 reference	
standard),	with	a	DOR	of	43.13.	This	excellent	value	supports	the	
diagnostic	usefulness	of	PAX2	immunohistochemistry,	suggesting	
its	 introduction	as	routine	diagnostic	test	 in	support	of	histologic	
examination.	Given	its	high	specificity	(95%),	it	might	be	extremely	
important	in	reducing	the	rate	of	a	serious	overtreatment—hyster‐
ectomy	being	the	reference	standard	therapy	for	precancerous	EH.	
On	the	other	hand,	the	sensibility	observed	(72%)	appeared	to	be	
more	than	enough	for	a	support	test.	In	fact,	since	PAX2	loss	may	
rarely	be	found	in	NE	and	benign	EH,	it	is	fundamental	to	identify	
a	lesional	focus	of	interest	by	hematoxylin	&	eosin	staining	before	
performing	PAX2	immunohistochemistry.	As	pointed	out	by	Joiner	
et	al,	it	is	always	necessary	to	correlate	histomorphologic	and	im‐
munohistochemical	findings.17
Our	results	also	suggest	the	better	accuracy	of	the	EIN	sys‐
tem	in	identifying	early	precancerous	lesions,	when	overt	cyto‐
logic	atypia	 is	 still	 absent.	Such	a	 finding	 is	 in	accordance	with	
the	results	of	our	previous	review	regarding	Bcl‐2	expression	in	
EH.35	The	EIN	system	is	based	on	three	main	histomorphologic	
features	 (glandular	 crowding,	 lesion	 diameter	 >1	mm,	 cytology	
different	 from	 adjacent	 endometrium)	 and	 a	 careful	 exclusion	
of	benign	mimics	 (eg,	polyps,	 secretory	changes)	and	cancer.2,3 
PAX2	 loss	may	 be	 used	 as	 an	 adjuvant	 finding	 for	 the	 EIN	 di‐
agnosis	when	comparison	with	NE	 is	not	possible,	or	 there	 is	a	
secretory	pattern	as	background	endometrium,	as	suggested	by	
Quick	et	al.36
Further	 studies	would	be	necessary	 to	validate	 these	excellent	
results.	Moreover,	it	would	also	be	interesting	to	study	the	possible	
role	of	PAX2	as	predictive	markers	of	response	to	conservative	treat‐
ment	in	EH,	as	for	other	markers.37	Raffone	A.	Unpublished	data.
To	the	best	of	our	knowledge,	this	study	is	the	first	systematic	
review	 specifically	 assessing	 the	 immunohistochemical	 expression	
changes	of	PAX2	in	NE,	benign	and	precancerous	EH,	and	EC,	evalu‐
ating its behavior in endometrial carcinogenesis.
To	date,	this	study	is	also	the	first	meta‐analysis	calculating	the	
diagnostic	accuracy	of	PAX2	immunohistochemical	evaluation	in	dif‐
ferential	diagnosis	of	benign	and	precancerous	EH.
We	analyzed	PAX2	diagnostic	accuracy	in	terms	of	both	loss	and	
decrease	of	expression	and	in	terms	of	both	classification	systems	of	
EH	(WHO	and	EIN),	in	order	to	clarify	the	method	to	interpret	the	
immunostaining,	not	specified	in	the	2017	ESGO	guidelines.7
Limitations	of	our	results	may	arise	from	some	characteristics	of	
the	 included	 studies,	which	 showed	high	or	unclear	 risk	of	bias	 in	
several	domains	(Figure	2).
Methods	in	performing	the	primary	studies	were	uneven.	Details	
about	the	study	protocol,	baseline	characteristics	of	the	patients	and	
thorough	analysis	of	confounding	factors	were	lacking	in	several	stud‐
ies.	Moreover,	the	method	to	grade	the	expression	of	PAX2	needs	to	
be	 standardized	 in	 terms	of	 intensity	of	 staining	and	percentage	of	
stained	glands.	However,	we	found	the	best	results	for	a	complete	loss	
of	PAX2,	which	may	be	easily	read	even	without	a	validated	method.
5  | CONCLUSION
Both	 complete	 loss	 and	 decrease	 of	 PAX2	 expression	 were	 sig‐
nificantly	more	common	 in	EC	and	precancerous	EH	than	benign	
EH,	 suggesting	 a	 tumor	 suppressor	 action	 of	 the	 PAX2 gene in 
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endometrial carcinogenesis. However, an oncogenic role cannot be 
excluded.
Immunohistochemistry	for	PAX2	may	be	an	accurate	routine	test	
to	aid	the	histomorphologic	differential	diagnosis	of	EH;	in	particu‐
lar	a	complete	loss	of	PAX2	expression	with	EIN	criteria	showed	an	
excellent	diagnostic	accuracy,	with	high	specificity.	Moreover,	PAX2	
loss	may	 identify	precancerous	EH	even	 in	the	absence	of	evident	
cytologic	atypia.
Further	 studies	 are	 necessary	 to	 confirm	 and	 validate	 these	
results.
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